Oncodesign is a modern biopharmaceutical company. For over 20 years, we are pioneers in translational medicine, from creating experimental new models through to the development of new approaches to assess the efficacy of treatments, such as pharmaco-imaging. We have targeted kinases, a family of key enzymes in maintaining cellular homeostasis, as numerous diseases occur through the dysregulation of kinases. We design powerful kinase inhibitors specific to each kinase, then we investigate the therapeutic potential of these small cyclic molecules. Harnessing our Nanocyclix technology, we have launched several promising Drug Discovery programs, both under partnerships and as proprietary developments.

We are currently working on identifying the sub-populations of patients resistant or unresponsive to therapies so that we can offer them effective treatments. We devise mathematical algorithms that can detect these patients from their clinical and biological data. This multidisciplinary approach can help to identify new targets playing a crucial role in overcoming resistance to treatments.

Leveraging our organic growth, we have accelerated our development by plugging gaps in our skill set and our technologies using our own financial resources through an IPO and complimentary acquisitions. These have included GSK’s research center in France and its specialized drug discovery teams, plus Bertin Pharma’s regulatory bioanalysis services arm. Our skill set now extends to oncology, immuno-inflammation, fibrosis, central nervous system, metabolism, cardiology and infectiology. Oncology is a powerful knowledge driver that allows us to apply our innovation to new therapeutic areas.

Oncodesign’s culture is collaborative first and foremost because we will always be stronger together in our efforts to build the world for the generations to come. We have naturally grown to become experts in precision medicine. Oncodesign aims to imbue its commitment to healthcare with meaning.